DC therapy for metastatic melanoma

References

• South Australian Cancer Registry (1996). Epidermiology of cancer in South Australia. Incidence, mortality and survival 1977— 1995. Incidence and Mortality 1995.
   Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271— 96.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F', Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767— 811.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control ofimmunity. Nature 1998;392:245–52.
   PubMed Web of Science ®Google Scholar
• Cella M, Sallusto F', Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10— 6.
   Google Scholar
• Lotze MT Not just an antigen-presenting cell: 5th internationalsymposium on dendritic cells in fundamental and clinical immunology. y Leukoc Biol 1999;66:195— 200.
   PubMed Web of Science ®Google Scholar
• Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. y Exp Med 1997;186:1183— 7.
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. y Exp Med 1996;183:317–22.
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulseddendritic cells induce antigen-specific CTL-mediated protective tumor immunity. y Exp Med 1996;183:283— 7.
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297— 302.
   PubMed Web of Science ®Google Scholar
• Lopez JA, Hart DN. Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther 2002;4:54–63.
   PubMed Web of Science ®Google Scholar
• O'Rourke MG, Johnson M, Lanagan C et al. Durable completeclinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387— 95.
   Google Scholar
• Romani N, Gruner S, Brang D et al. Proliferating dendritic cellprogenitors in human blood. y Exp Med 1994;180:83–93.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus inter-leukin 4 and downregulated by rumor necrosis factor alpha. y Exp Med 1994;179:1109–18.
   PubMed Web of Science ®Google Scholar
• Caux C, Dezutter-Dambuyant C, Schmitt D et al. GM-CSF andTNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258–61.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Farhood H, Wilson CW et al. Dendritic cell therapy of cancer and HIV infection. In: Lotze MT, Thomson A, editors. Dendritic cells: biology and clinical applications. San Diego: Academic Press, 1999: 459–85.
   Google Scholar
• Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanomapatients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced Stage IV melanoma. 7 Exp Med 1999;190:1669–78.
   PubMed Web of Science ®Google Scholar
• Trefzer U, Weingart G, Chen Yet al. Hybrid cell vaccination forcancer immune therapy: first clinical trial with metastatic melanoma. Int y Cancer 2000;85:618–26.
   Google Scholar
• Panelli MC, Wunderlich J, Jeffries J et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the mela-noma-associated antigens MART-1 and gp100. 7 Immunotber 2000;23:487–98.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Herbst B, Chen JL et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(± ) hematopoietic progeni-tor cells. Int y Cancer 2000;86:385–92.
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Dieckmann D, Keikavoussi P et al. Mage-3and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1melanoma patientsby mature monocyte-derived dendritic cells. 7 Immunol 2000;165: 3492–6.
   Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(± ) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451–8.
   PubMed Web of Science ®Google Scholar
• Toungouz M, Libin M, Bulte F et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vac-cination with dendritic cells pulsed with MAGE peptides in patients with mage-Al /A3-positive rumors. 7 Leukoc Biol 2001;69:937–43.
   PubMed Web of Science ®Google Scholar
• Chang AE, Redman BG, Whitfield JR et al. A Phase I trial of rumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021–32.
   PubMed Web of Science ®Google Scholar
• Lau R, Wang E Jeffrey G et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. 7 Immunotber 2001;24:66–78.
   Google Scholar
• Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int y Cancer 2001;93:243–51.
   PubMed Web of Science ®Google Scholar
• Andersen MH, Keikavoussi P, Brocker EB et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int 7 Cancer 2001;94:820–4.
   PubMed Web of Science ®Google Scholar
• Smithers M, O'Connell K, MacFadyen S et al. Clinical response after intradermal immature dendritic cell vaccination in meta-static melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 2003;52:41–52.
   Google Scholar
• Thomas R, Padmanabha J, Chambers M et al. Metastatic lesionsin the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma. Mela-noma Res 2001;11:167–73.
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47–64.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175–82.
   PubMedGoogle Scholar
• Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267–8.
   Google Scholar
• Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of theimmunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. 7 Exp Med 1994;180:347–52.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Brichard V, Van Pel A et al. A new gene coding for adifferentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. 7 Exp Med 1994;180:35–42.
   Google Scholar
• Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multipleepitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. 7 Immunol 1995;154:3961–8.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the genecoding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515–9.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by rumor-infiltrating lymphocytes associated with in vivo rumor rejection. Proc Natl Acad Sci USA 1994;91:6458–62.
   PubMed Web of Science ®Google Scholar
• Schreiber H. Tumour immunology. In: Paul WE, editor. Fundamental immunology. Philadelphia: Lippincott-Raven Publish-ers, 1999: 1237–70.
   Google Scholar
• Pardoll DM. Cancer vaccines. Nat Med 1998;4:525–31.
   PubMed Web of Science ®Google Scholar
• Velders MP, Nieland JD, Rudolf MP et al. Identification of peptides for immunotherapy of cancer. It is worth the effort. Grit Rev Immunol 1998;18:7–27.
   PubMed Web of Science ®Google Scholar
• Boland CR, Ricciardiello L. How many mutations does it take to make a tumor? Proc Natl Acad Sci USA 1999;96:14675–7.
   PubMed Web of Science ®Google Scholar
• Van den Eynde BJ, Van de Bruggen P. T cell defined tumour antigens. Curr Opin Immunol 1997;9:684–93.
   PubMed Web of Science ®Google Scholar
• Miller AB. Breast Cancer. Cancer 1981;47:1109–13.
   PubMed Web of Science ®Google Scholar
• Meyskens FL, Loescher L, Serokman R et al. Potential uses of biological response modifiers (BRM) in the adjuvant treatment of melanoma and results from a trial of BCG / - vitamin A. Adjuv Tber Cancer 1994;4.
   Google Scholar